324 related articles for article (PubMed ID: 27476449)
1. Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors.
Escuin-Ordinas H; Li S; Xie MW; Sun L; Hugo W; Huang RR; Jiao J; de-Faria FM; Realegeno S; Krystofinski P; Azhdam A; Komenan SM; Atefi M; Comin-Anduix B; Pellegrini M; Cochran AJ; Modlin RL; Herschman HR; Lo RS; McBride WH; Segura T; Ribas A
Nat Commun; 2016 Aug; 7():12348. PubMed ID: 27476449
[TBL] [Abstract][Full Text] [Related]
2. COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.
Escuin-Ordinas H; Atefi M; Fu Y; Cass A; Ng C; Huang RR; Yashar S; Comin-Anduix B; Avramis E; Cochran AJ; Marais R; Lo RS; Graeber TG; Herschman HR; Ribas A
Mol Oncol; 2014 Mar; 8(2):250-60. PubMed ID: 24345644
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical oncogenesis: are all BRAF inhibitors equal?
Menzies AM; Kefford RF; Long GV
Pigment Cell Melanoma Res; 2013 Sep; 26(5):611-5. PubMed ID: 23795808
[TBL] [Abstract][Full Text] [Related]
4. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
6. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
Su F; Viros A; Milagre C; Trunzer K; Bollag G; Spleiss O; Reis-Filho JS; Kong X; Koya RC; Flaherty KT; Chapman PB; Kim MJ; Hayward R; Martin M; Yang H; Wang Q; Hilton H; Hang JS; Noe J; Lambros M; Geyer F; Dhomen N; Niculescu-Duvaz I; Zambon A; Niculescu-Duvaz D; Preece N; Robert L; Otte NJ; Mok S; Kee D; Ma Y; Zhang C; Habets G; Burton EA; Wong B; Nguyen H; Kockx M; Andries L; Lestini B; Nolop KB; Lee RJ; Joe AK; Troy JL; Gonzalez R; Hutson TE; Puzanov I; Chmielowski B; Springer CJ; McArthur GA; Sosman JA; Lo RS; Ribas A; Marais R
N Engl J Med; 2012 Jan; 366(3):207-15. PubMed ID: 22256804
[TBL] [Abstract][Full Text] [Related]
7. Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation.
Roh MR; Kim JM; Lee SH; Jang HS; Park KH; Chung KY; Rha SY
J Dermatol; 2015 Sep; 42(9):881-8. PubMed ID: 26047064
[TBL] [Abstract][Full Text] [Related]
8. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
12. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
13. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
14. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
15. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
16. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
[TBL] [Abstract][Full Text] [Related]
17. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
Capovilla M
Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
[TBL] [Abstract][Full Text] [Related]
18. RAF inhibitors that evade paradoxical MAPK pathway activation.
Zhang C; Spevak W; Zhang Y; Burton EA; Ma Y; Habets G; Zhang J; Lin J; Ewing T; Matusow B; Tsang G; Marimuthu A; Cho H; Wu G; Wang W; Fong D; Nguyen H; Shi S; Womack P; Nespi M; Shellooe R; Carias H; Powell B; Light E; Sanftner L; Walters J; Tsai J; West BL; Visor G; Rezaei H; Lin PS; Nolop K; Ibrahim PN; Hirth P; Bollag G
Nature; 2015 Oct; 526(7574):583-6. PubMed ID: 26466569
[TBL] [Abstract][Full Text] [Related]
19. Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects.
Escuin-Ordinas H; Liu Y; Sun L; Hugo W; Dimatteo R; Huang RR; Krystofinski P; Azhdam A; Lee J; Comin-Anduix B; Cochran AJ; Lo RS; Segura T; Scumpia PO; Ribas A
PLoS One; 2021; 16(6):e0252597. PubMed ID: 34161353
[TBL] [Abstract][Full Text] [Related]
20. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
